

Introducing the Roche HPV Self-Sampling Solution

Empowering women to eliminate cervical cancer



Why invest now in Roche HPV self-sampling?

Roche self-sampling provides a solution to improve:

More than 50% of new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.¹

Accessibility

- Serves the unscreened population (screening programs cover only 19% of women in developing countries, compared to 63% in developed countries)¹
- Increases attendance in screening programs by reducing logistical barriers

Empowerment

- Enables women to better manage their own health
- Provides privacy and convenience
- Reduces some of the barriers that prevent women from participating in a screening program, such as social stigma, discomfort, and embarrassment

Outcomes

- Majority of cervical cancer cases occur in unscreened women²
- Screening provides the opportunity to detect pre-cancer and prevent progression to cervical cancer
- No woman should die from cervical cancer

Introducing the Roche HPV Self-Sampling Solution

Empowering women to eliminate cervical cancer



Why invest now in Roche HPV self-sampling?

Roche self-sampling provides a solution to improve:

More than 50% of new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.¹

Accessibility

- Serves the unscreened population (screening programs cover only 19% of women in developing countries, compared to 63% in developed counties)¹
- Increases attendance in screening programs by reducing logistical barriers

Empowerment

- Enables women to better manage their own health
- Provides privacy and convenience
- Reduces some of the barriers that prevent women from participating in a screening program, such as social stigma, discomfort, and embarrassment

Outcomes

- Majority of cervical cancer cases occur in unscreened women²
- Screening provides the opportunity to detect pre-cancer and prevent progression to cervical cancer
- No woman should die from cervical cancer

Introducing the Roche HPV Self-Sampling Solution

Empowering women to eliminate cervical cancer



Why invest now in Roche HPV self-sampling?

Roche self-sampling provides a solution to improve:

More than 50% of new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.¹

Accessibility

- Serves the unscreened population (screening programs cover only 19% of women in developing countries, compared to 63% in developed counties)¹
- Increases attendance in screening programs by reducing logistical barriers

Empowerment

- Enables women to better manage their own health
- Provides privacy and convenience
- Reduces some of the barriers that prevent women from participating in a screening program, such as social stigma, discomfort, and embarrassment

Outcomes

- Majority of cervical cancer cases occur in unscreened women²
- Screening provides the opportunity to detect pre-cancer and prevent progression to cervical cancer
- No woman should die from cervical cancer

Introducing the Roche HPV Self-Sampling Solution

Empowering women to eliminate cervical cancer



know *now*

*If women anywhere in the world are at risk for **cervical cancer***

Why invest now in Roche HPV self-sampling?

Roche self-sampling provides a solution to improve:

More than 50% of new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.¹

Accessibility

- Serves the unscreened population (screening programs cover only 19% of women in developing countries, compared to 63% in developed counties)¹
- Increases attendance in screening programs by reducing logistical barriers

Empowerment

- Enables women to better manage their own health
- Provides privacy and convenience
- Reduces some of the barriers that prevent women from participating in a screening program, such as social stigma, discomfort, and embarrassment

Outcomes

- Majority of cervical cancer cases occur in unscreened women²
- Screening provides the opportunity to detect pre-cancer and prevent progression to cervical cancer
- No woman should die from cervical cancer

Introducing the Roche HPV Self-Sampling Solution

Empowering women to eliminate cervical cancer



*If women anywhere in the world are at risk for **cervical cancer***

Why invest now in Roche HPV self-sampling?

Roche self-sampling provides a solution to improve:

More than 50% of new cervical cancers are in women who have never been screened or have not been screened in the previous 5 years of their lives.¹

Accessibility

- Serves the unscreened population (screening programs cover only 19% of women in developing countries, compared to 63% in developed counties)¹
- Increases attendance in screening programs by reducing logistical barriers

Empowerment

- Enables women to better manage their own health
- Provides privacy and convenience
- Reduces some of the barriers that prevent women from participating in a screening program, such as social stigma, discomfort, and embarrassment


Outcomes

- Majority of cervical cancer cases occur in unscreened women²
- Screening provides the opportunity to detect pre-cancer and prevent progression to cervical cancer
- No woman should die from cervical cancer

How does Roche HPV Self-Sampling work?

4 simple steps from sample collection to test result

1. Sample collection



Following the device manufacturer's instructions, **woman collects her own specimen** and hands over swab to healthcare worker

2. Sample suspension




Healthcare worker suspends self collected specimen into 20 ml Roche Cell Collection Medium or PreservCyt® (ThinPrep®) Solution (primary vial) following suspension instructions (scan QR code for instructional video)

3. Sample transportation



Primary vial is transported to the laboratory for further analysis

4. Sample testing



Primary vial is processed following **cobas® 4800 HPV Test** or **cobas® HPV** for use on **cobas® 6800/8800** systems workflow and results are reported following local protocols/ infrastructure

“A major barrier for women across many cultures has been the requirement to undergo a speculum examination. With the emergence of HPV-based primary screening, the option of self-collection... may overcome this barrier, given that such samples when tested using PCR-based HPV assays have similar sensitivity for the detection of cervical pre-cancers as practitioner-collected cervical specimens.”²

How do we know self-sampling is efficacious?

Overall, our study shows over 90% correlation

between clinician collected endocervical and self-collected vaginal specimens

		Clinician-Collected Cervical Sample 14 hrHPV Result		
		Positive	Negative	Total
Self-Collected Vaginal Sample using FLOQSwabs 552C.80 14 hrHPV Result	Positive	165	43	208
	Negative	26	472	498
	Total	191	515	706
		Result %	95% Confidence Interval	
Positive Percent Agreement		86.4%	80.8% - 90.5%	
Negative Percent Agreement		91.7%	88.9% - 93.7%	
Overall Percent Agreement		90.2%	87.8% - 92.2%	

Correlation of results for self-collected vaginal specimens using FLOQSwabs 552C.80 and clinician-collected cervical specimens tested on **cobas® HPV** for use on **cobas® 6800/8800**

Offer your patients more options - tell them about HPV Self-Sampling today.

- NIH Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2429949/#:~:text=Our%20analysis%20of%20population%2Dbased,Bangladesh%20to%2073%25%20in%20Brazil](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2429949/#:~:text=Our%20analysis%20of%20population%2Dbased,Bangladesh%20to%2073%25%20in%20Brazil.). Accessed 31 May, 2022.
- CDC “Cervical cancer is preventable”, [https://www.cdc.gov/vitalsigns/cervical-cancer/index.html#:~:text=Up%20to%2093%25%20of%20cervical,that%20cause%20most%20cervical%20cancers](https://www.cdc.gov/vitalsigns/cervical-cancer/index.html#:~:text=Up%20to%2093%25%20of%20cervical,that%20cause%20most%20cervical%20cancers.). Accessed 31 May, 2022.
- NIH “Self-Collection for Cervical Screening Programs: From Research to Reality”, [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226191](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226191.). Accessed 31 May, 2022.

โฆษณาโดยตรงต่อผู้ประกอบการวิชาชีพทางการแพทย์ และสาธารณสุขที่ได้รับการยกเว้นโดยไม่ต้องขออนุญาต

[Find out more on cobas.com](https://www.roche.com/cobas)

COBAS and CINTEC, are trademarks of Roche.
MC-TH-00832 Valid till 31 Oct 2025
AN6501428

Roche Diagnostics (Thailand) Ltd.
18-19th Floor Rasa Tower 1 555 Phaholyothin Road, Chatuchak Chatuchak,
Bangkok 10900 Thailand

อ่านค่าเตือนในหลอดและ
เอกสารกำกับเครื่องมือแพทย์ก่อนใช้

